NCT05181592 - Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Luspatercept

Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)

Trial Locations (13)

Medizinische Universität Wien, Vienna

Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor, Bern

Universitätsspital Basel, Basel

Medizinische Universität Innsbruck, Innsbruck

Clinica di Ematologia Istituto oncologico della Svizzera Italiana, Bellinzona

Institut Català d' Oncologia de Badalona, Badalona

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario Central de Asturias, Oviedo

University Hospital of Salamanca, Salamanca

Hospital Universitario y Politecnico La Fe de Valencia, Valencia

Klinikum rechts der Isar, München

Universitätsklinikum Leipzig, Leipzig

Hospital Vall d´Hebron, Barcelona